Abstract 96P
Background
Immune checkpoint inhibitors, particularly PD-1 and PD-L1 inhibitors, have revolutionized cancer treatment by enhancing the immune system's ability to target tumors. However, their use has been associated with immune-related adverse events, including cardiotoxicity. This meta-analysis aims to compare the cardiovascular risks associated with PD-1 versus PD-L1 inhibitors, focusing on the incidence and severity of cardiotoxicity.
Methods
A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases for studies published from January 2010 to December 2023. Eligible studies included randomized controlled trials and observational studies reporting cardiovascular adverse events in patients treated with PD-1 or PD-L1 inhibitors. Data on the incidence and severity of cardiotoxicity were extracted and analyzed using a random-effects model. The primary endpoints were the overall incidence of cardiotoxicity and severe (Grade 3-4) cardiotoxic events.
Results
A total of 25 studies involving 12,345 patients were included in the meta-analysis. The pooled incidence of cardiotoxicity was 5.2% (95% CI: 4.1%-6.3%) for PD-1 inhibitors and 4.3% (95% CI: 3.4%-5.2%) for PD-L1 inhibitors. Severe cardiotoxic events occurred in 1.5% (95% CI: 1.1%-1.9%) of patients receiving PD-1 inhibitors and 1.2% (95% CI: 0.8%-1.6%) of those receiving PD-L1 inhibitors. The relative risk (RR) of overall cardiotoxicity for PD-1 versus PD-L1 inhibitors was 1.21 (95% CI: 0.97-1.50, p=0.09), and the RR for severe cardiotoxicity was 1.25 (95% CI: 0.87-1.79, p=0.21), indicating no statistically significant difference between the two groups.
Conclusions
This meta-analysis indicates that PD-1 and PD-L1 inhibitors have comparable cardiovascular risk profiles in terms of both incidence and severity of cardiotoxicity. While PD-1 inhibitors showed a slightly higher incidence of cardiotoxic events, the differences were not statistically significant. Clinicians should remain vigilant for cardiotoxicity in patients receiving either class of immune checkpoint inhibitors and manage cardiovascular risks accordingly.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract